BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35430568)

  • 1. Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions.
    Massimino M; Stella S; Micale G; Motta L; Pavone G; Broggi G; Piombino E; Magro G; Soto Parra HJ; Manzella L; Vigneri P
    Cancer Genomics Proteomics; 2022; 19(3):350-361. PubMed ID: 35430568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
    Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
    Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic mutation analysis in melanoma using targeted next generation sequencing.
    Miraflor AP; de Abreu FB; Peterson JD; Turner SA; Amos CI; Tsongalis GJ; Yan S
    Exp Mol Pathol; 2017 Oct; 103(2):172-177. PubMed ID: 28822769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
    Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
    Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
    Hutchinson KE; Lipson D; Stephens PJ; Otto G; Lehmann BD; Lyle PL; Vnencak-Jones CL; Ross JS; Pietenpol JA; Sosman JA; Puzanov I; Miller VA; Pao W
    Clin Cancer Res; 2013 Dec; 19(24):6696-702. PubMed ID: 24345920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach.
    Manca A; Paliogiannis P; Colombino M; Casula M; Lissia A; Botti G; Caracò C; Ascierto PA; Sini MC; Palomba G; Pisano M; ; ; Doneddu V; Cossu A; Palmieri G;
    J Transl Med; 2019 Aug; 17(1):289. PubMed ID: 31455347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of an NGS mutation detection panel for melanoma.
    Reiman A; Kikuchi H; Scocchia D; Smith P; Tsang YW; Snead D; Cree IA
    BMC Cancer; 2017 Feb; 17(1):150. PubMed ID: 28228113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
    Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing.
    Boussemart L; Nelson A; Wong M; Ross JS; Sosman J; Mehnert J; Daniels G; Kendra K; Ali SM; Miller VA; Schrock AB
    Oncologist; 2019 May; 24(5):657-663. PubMed ID: 30683711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of distinct molecular profile of Primary Dermal Melanoma.
    Shaigany S; Tessier-Cloutier B; Busam KJ; Horst BA
    Hum Pathol; 2020 Dec; 106():32-38. PubMed ID: 32946880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.
    Silva JM; Bulman C; McMahon M
    Mol Cancer Res; 2014 Mar; 12(3):447-63. PubMed ID: 24425783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma.
    Franczak C; Salleron J; Dubois C; Filhine-Trésarrieu P; Leroux A; Merlin JL; Harlé A
    Mol Diagn Ther; 2017 Apr; 21(2):209-216. PubMed ID: 28130756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study.
    Casula M; Paliogiannis P; Ayala F; De Giorgi V; Stanganelli I; Mandalà M; Colombino M; Manca A; Sini MC; Caracò C; Ascierto PA; Satta RR; ; Lissia A; Cossu A; Palmieri G;
    BMC Cancer; 2019 Aug; 19(1):772. PubMed ID: 31382929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
    Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
    PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Application of Next-Generation Sequencing-Based Panel to
    Park C; Kim M; Kim MJ; Kim H; Ock CY; Keam B; Kim TM; Kim DW; Kim JI; Heo DS
    Mol Cancer Ther; 2020 Mar; 19(3):937-944. PubMed ID: 31826932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the Diagnostic Yield of Targeted Next-Generation Sequencing for Melanoma and Gastrointestinal Tumors.
    Garg S; Grenier S; Misyura M; Sukhai MA; Thomas M; Kamel-Reid S; Stockley T
    J Mol Diagn; 2020 Apr; 22(4):467-475. PubMed ID: 32036084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma.
    Zhu ML; Zhou L; Sadri N
    Virchows Arch; 2018 Sep; 473(3):371-377. PubMed ID: 29926184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.
    Wheler J; Yelensky R; Falchook G; Kim KB; Hwu P; Tsimberidou AM; Stephens PJ; Hong D; Cronin MT; Kurzrock R
    BMC Cancer; 2015 Feb; 15():61. PubMed ID: 25886620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.
    Uguen A; Guéguen P; Legoupil D; Bouvier S; Costa S; Duigou S; Lemasson G; Ledé F; Sassolas B; Talagas M; Férec C; Le Maréchal C; De Braekeleer M; Marcorelles P
    Hum Pathol; 2015 Nov; 46(11):1582-91. PubMed ID: 26297254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.